论文部分内容阅读
目的:观察利妥昔单抗联合化疗治疗B细胞非霍奇淋巴瘤(NHL)的临床疗效及IPI评分对预后的影响。方法:21例B细胞NHL患者,利妥昔单抗联合CHOP方案4～8个疗程。结果:CR 14例,总有效率90.5%;2 a疾病无进展生存率(69.74±10.43)%,2 a总生存率(84.44±8.35)%。IPI评分0～2分者CR率93.3%,总有效率100%,3～5分者CR率0,总有效率66.6%。结论:R-CHOP方案疗效满意,安全性较好,IPI 0～2分者缓解率明显高于3～5分者。
Objective: To observe the clinical efficacy of rituximab combined with chemotherapy in the treatment of non-Hodgkin’s lymphoma of the B-cell (NHL) and the effect of IPI score on the prognosis. Methods: 21 patients with B cell NHL, rituximab combined with CHOP program 4 to 8 courses. Results: CR 14 cases, the total efficiency of 90.5%; 2 a disease progression-free survival rate (69.74 ± 10.43)%, 2-year overall survival rate (84.44 ± 8.35)%. IPI score 0 ~ 2 points CR rate of 93.3%, the total effective rate of 100%, 3 ~ 5 CR rate of 0, the total effective rate of 66.6%. Conclusion: The R-CHOP regimen has satisfactory curative effect and safety, and the remission rate of 0 ~ 2 patients with IPI is obviously higher than 3 ~ 5 patients.